BELLUS Health Inc (BLU) - Financial and Strategic SWOT Analysis Review

May 2021 | 48 pages | ID: BDDA559B3BBEN
GlobalData

Abstracts

BELLUS Health Inc (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BELLUS Health Inc (BELLUS Health) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for treating patients with chronic cough and hypersensitization-related disorders. The company’s lead product, BLU-593 (formerly NEO5937) is a potent, orally bio-available, highly selective small molecule antagonist of the P2X3 receptor which is being developed for treating refractory chronic cough, and chronic pruritus associated with atopic dermatitis. It has license agreement and collaborations with NEOMED institute for the development and commercialization of BLU-593. The company operates in Canada and the US through its subsidiaries. BELLUS Health is headquartered in Laval, Quebec, Canada.

BELLUS Health Inc Key Recent Developments

May 10,2021: BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
Apr 13,2021: BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference
Mar 24,2021: BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors
Feb 25,2021: BELLUS Health reports year 2020 financial results and business highlights
Feb 22,2021: BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

BELLUS Health Inc - Key Facts
BELLUS Health Inc - Key Employees
BELLUS Health Inc - Key Employee Biographies
BELLUS Health Inc - Major Products and Services
BELLUS Health Inc - History
BELLUS Health Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
BELLUS Health Inc - Business Description
BELLUS Health Inc - Corporate Strategy
BELLUS Health Inc - SWOT Analysis
SWOT Analysis - Overview
BELLUS Health Inc - Strengths
BELLUS Health Inc - Weaknesses
BELLUS Health Inc - Opportunities
BELLUS Health Inc - Threats
BELLUS Health Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BELLUS Health Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 10, 2021: BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
Apr 13, 2021: BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference
Mar 24, 2021: BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors
Feb 25, 2021: BELLUS Health reports year 2020 financial results and business highlights
Feb 22, 2021: BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
Dec 07, 2020: BELLUS Health appoints Ramzi Benamar as Chief Financial Officer
Nov 12, 2020: BELLUS Health reports third quarter 2020 financial results and business highlights
Aug 13, 2020: BELLUS Health reports second quarter 2020 financial results and business highlights
May 14, 2020: BELLUS Health reports first quarter 2020 financial results and business highlights, and Provides updates on BLU-5937
Feb 27, 2020: BELLUS Health reports full year 2019 financial results and business highlights on BLU-5937

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

BELLUS Health Inc, Key Facts
BELLUS Health Inc, Key Employees
BELLUS Health Inc, Key Employee Biographies
BELLUS Health Inc, Major Products and Services
BELLUS Health Inc, History
BELLUS Health Inc, Subsidiaries
BELLUS Health Inc, Key Competitors
BELLUS Health Inc, Ratios based on current share price
BELLUS Health Inc, Annual Ratios
BELLUS Health Inc, Annual Ratios (Cont...1)
BELLUS Health Inc, Interim Ratios
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BELLUS Health Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

BELLUS Health Inc, Performance Chart (2016 - 2020)
BELLUS Health Inc, Ratio Charts
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021